BioLine Rx (FRA:YP2) Buyback Yield %: -24.48 (As of Jul. 05, 2026)


FRA:YP2 BioLine Rx Ltd FRA:YP2
21 GF Score
Price €2.52
! 5 Warning Signs
View Full Analysis

What is BioLine Rx Buyback Yield %?

BioLine Rx FRA:YP2 -0.79% 21 Buyback Yield % is -24.48 as of Jul. 05, 2026. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review. Among 741 Biotechnology companies, BioLine Rx ranks worse than 71.93% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

BioLine Rx's current buyback yield was -24.48%.

BioLine Rx Buyback Yield % Historical Data

* Premium members only.

The historical data trend for BioLine Rx's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx Buyback Yield % Chart

BioLine Rx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -52.27 -42.37 -12.92 -108.20 -122.29

BioLine Rx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -191.24 -114.18 -124.31 -99.74 -28.25

FRA:YP2 vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, BioLine Rx's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Buyback Yield % falls into.


FRA:YP2
21GF Score
BioLine Rx Ltd FRA:YP2
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

BioLine Rx's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 11.865) / 9.70273
=-122.29%

BioLine Rx's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 2.767) / 7.457614
=-37.10%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -24.48 mean?
BioLine Rx (FRA:YP2) has a Buyback Yield % of -24.48 as of Jul. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BioLine Rx and its competitors. According to the industry distribution chart, BioLine Rx ranks #533 out of 741 companies in the Biotechnology industry, placing it in the top 71.9%.
Is BioLine Rx's Buyback Yield % too high?
BioLine Rx's current Buyback Yield % is -24.48. Based on the distribution chart, BioLine Rx ranks #533 out of 741 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLine Rx ranks #533 out of 741 companies for Buyback Yield %. This places BioLine Rx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BioLine Rx and its competitors. BioLine Rx's current Buyback Yield % is -24.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (FRA:YP2) has a current Buyback Yield % of -24.48. The current Buyback Yield % is -24.48. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current Buyback Yield % is -24.48 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Other Exchanges BLRX:USABLRX:Israel
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score

Get the complete analysis for FRA:YP2

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price